302 related articles for article (PubMed ID: 24802342)
1. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
Ferraresso M; Belingheri M; Ginevri F; Murer L; Dello Strologo L; Cardillo M; Parodi A; Ghirardo G; Guzzo I; Innocente A; Ghio L
Pediatr Transplant; 2014 Jun; 18(4):350-6. PubMed ID: 24802342
[TBL] [Abstract][Full Text] [Related]
2. Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine A, and steroid elimination: 3-year data.
Pape L; Lehner F; Blume C; Ahlenstiel T
Transplantation; 2011 Sep; 92(6):658-62. PubMed ID: 21804444
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
6. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
7. De novo therapy with everolimus and reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study.
Grushkin C; Mahan JD; Mange KC; Hexham JM; Ettenger R
Pediatr Transplant; 2013 May; 17(3):237-43. PubMed ID: 23279564
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
9. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
10. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
11. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
Ettenger R; Hoyer PF; Grimm P; Webb N; Loirat C; Mahan JD; Mentser M; Niaudet P; Offner G; Vandamme-Lombaerts R; Hexham JM;
Pediatr Transplant; 2008 Jun; 12(4):456-63. PubMed ID: 18466433
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
[TBL] [Abstract][Full Text] [Related]
13. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.
Krämer BK; Neumayer HH; Stahl R; Pietrzyk M; Krüger B; Pfalzer B; Bourbigot B; Campbell S; Whelchel J; Eris J; Vitko S; Budde K;
Transplant Proc; 2005 Apr; 37(3):1601-4. PubMed ID: 15866684
[TBL] [Abstract][Full Text] [Related]
14. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Mai D; Dandel M; Knosalla C; Hiemann NE; Grauhan O; Huebler M; Pasic M; Weng Y; Meyer R; Rothenburger M; Hummel M; Hetzer R
J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; James S; Zuppan C; Franco E; Concepcion W
Pediatr Transplant; 2005 Feb; 9(1):80-3. PubMed ID: 15667617
[TBL] [Abstract][Full Text] [Related]
16. Correlations with six-month protocol biopsy findings in pediatric transplant recipients on low- and regular-dose CNI regimens.
Kanzelmeyer NK; Ahlenstiel T; Kreuzer M; Becker JU; Pape L
Clin Transplant; 2013; 27(2):319-23. PubMed ID: 23414365
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial.
Höcker B; Weber LT; Bunchman T; Rashford M; Tönshoff B;
Pediatr Transplant; 2005 Aug; 9(4):504-11. PubMed ID: 16048604
[TBL] [Abstract][Full Text] [Related]
18. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
[TBL] [Abstract][Full Text] [Related]
19. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
20. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
